Mode
Text Size
Log in / Sign up

High THBS1 expression is associated with poorer outcomes in patients with sepsisHigh THBS1 levels linked to poorer outcomes in sepsis patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that high THBS1 expression is associated with poorer outcomes in sepsis, but evidence is currently preliminary.

This meta-analysis synthesizes data from multiple public datasets and an exploratory cohort of 23 patients with sepsis and 10 healthy controls to evaluate THBS1 expression. The analysis indicates that THBS1 transcript levels are consistently altered in sepsis across various public datasets. Furthermore, THBS1 expression was found to be more prominent in specific subsets of myeloid-related cell populations.

Key findings suggest that high THBS1 expression is associated with poorer outcomes, including survival. However, the authors note several significant limitations, including a small exploratory clinical cohort, substantial heterogeneity across the public datasets, and a lack of formal adjustment for disease severity in survival analysis. Additionally, the study lacks protein-level validation and functional experiments.

Due to these limitations, the results are considered preliminary and hypothesis-generating. While THBS1 is identified as a candidate molecule for myeloid immune responses in sepsis, it is not a validated biomarker. Clinical application is currently limited by the lack of functional data and the low certainty of the evidence.

How this fits prior evidence

This meta-analysis identifies THBS1 as a candidate molecule for myeloid immune responses in sepsis. This finding addresses a gap in identifying specific molecular drivers of the immune response. It provides a different focus than the reported finding that higher H3.1 nucleosome levels are associated with increased 28-day mortality and RRT risk in sepsis. Unlike the heparin meta-analysis which showed no mortality benefit, this study identifies a specific transcript associated with poorer outcomes, though it remains preliminary.

When a person develops sepsis, their body faces a life-threatening immune response. Researchers are looking for ways to better understand this process and identify markers that can help predict how a patient might fare. This study looked at a protein called THBS1 to see if it plays a role in the body's reaction to infection.

By looking at multiple public datasets and a small group of patients, the researchers found that THBS1 levels are consistently different in people with sepsis compared to healthy people. Specifically, this protein was more active in certain types of immune cells. Most importantly, the data showed that patients with high levels of THBS1 had poorer outcomes.

It is important to note that these findings are still very early. The study used a small group of patients and did not test the actual protein levels in the blood, only the genetic instructions for it. Because of these factors, the results are preliminary and are meant to help scientists identify new areas to study rather than provide a definitive test for doctors to use today.

What this means for you:
High levels of the THBS1 protein are linked to worse outcomes in patients with sepsis.

Common questions

What is THBS1 and why does it matter in sepsis?

THBS1 is a protein that shows up in the body's immune cells. In this study, researchers found that THBS1 levels were consistently different in people with sepsis compared to healthy people. Because high levels of this protein were linked to poorer outcomes, it may help researchers understand how the immune system reacts during a severe infection.

Can doctors use THBS1 to predict if a patient will get better?

Not yet. The study's findings are preliminary and are meant to generate new ideas for research. Because the study had a small sample size and did not test actual protein levels, the results are not yet ready to be used as a standard tool for making medical decisions. You should always talk to a doctor about specific treatments.

What were the limitations of this study?

The study had several limitations, including a small group of patients and a lack of protein-level testing. The researchers also did not perform functional experiments or adjust for how sick a patient was when looking at survival. These factors mean the results are currently used to identify potential areas for future study.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BackgroundSepsis remains a major cause of mortality worldwide, and biomarkers that integrate inflammatory dysregulation, immune-cell localization, and prognostic relevance remain limited. To identify a candidate molecule linked to myeloid immune responses in sepsis, we performed an integrated analysis of public bulk transcriptomic datasets, single-cell RNA sequencing data, a small exploratory clinical RNA-sequencing cohort, and compound screening analyses.ResultsDifferential expression analysis and meta-analysis across public datasets identified THBS1 as a consistently altered transcript in sepsis. In a small exploratory peripheral-blood transcriptomic cohort comprising 23 patients with sepsis and 10 healthy controls, THBS1 was selected for downstream analysis on the basis of its position in the public-data protein–protein interaction network and the subsequent THBS1-focused analyses. The reused clinical RNA-sequencing cohort was retained only as an exploratory description and was not used to claim independent validation. Single-cell analysis suggested that THBS1 expression was more prominent in subsets of myeloid-related cell populations. Survival analysis in an external dataset indicated that high THBS1 expression was associated with poorer outcomes, but this finding should be interpreted as exploratory because formal adjustment for disease severity was not possible. Candidate compounds associated with THBS1 were further prioritized by database mining and molecular docking.ConclusionsThis study provides transcriptomic and computational evidence suggesting that THBS1 may be associated with myeloid-related immune activity and adverse prognosis in sepsis. Because the clinical cohort was small, protein-level validation and functional experiments were not performed, and substantial heterogeneity was observed across public datasets, these findings should be interpreted as preliminary and hypothesis-generating.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.